CorMedix Inc. (CRMD)
Market Cap | 188.55M |
Revenue (ttm) | 29,702 |
Net Income (ttm) | -39.79M |
Shares Out | 54.81M |
EPS (ttm) | -0.86 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 509,751 |
Open | 3.60 |
Previous Close | 3.56 |
Day's Range | 3.50 - 3.63 |
52-Week Range | 2.57 - 6.09 |
Beta | 1.86 |
Analysts | Strong Buy |
Price Target | 14.60 (+312.43%) |
Earnings Date | Nov 14, 2023 |
About CRMD
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath and Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly know... [Read more]
Financial Performance
In 2022, CorMedix's revenue was $65,408, a decrease of -65.74% compared to the previous year's $190,936. Losses were -$29.70 million, 5.29% more than in 2021.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for CRMD stock is "Strong Buy." The 12-month stock price forecast is $14.6, which is an increase of 312.43% from the latest price.
News

CorMedix Inc. Announces Partnership With The Leapfrog Group
– CorMedix to advocate for patient safety and infection prevention as part of Leapfrog's Partners Advisory Committee

CorMedix Inc. Announces FDA Approval of DefenCath® to Reduce the Incidence of Catheter-Related Bloodstream Infections in Adult Hemodialysis Patients
– First and only FDA-approved antimicrobial catheter lock solution in the U.S. – Company expects DefenCath to be available in Q1 2024 in the inpatient setting BERKELEY HEIGHTS, N.J., Nov. 15, 2023 (GL...

U.S. FDA approves CorMedix's antimicrobial drug
The U.S. Food and Drug Administration (FDA) on Wednesday approved CorMedix's antimicrobial drug that aims to reduce catheter-related bloodstream infections (CRBSIs) in patients with kidney disease, th...

CorMedix Inc. Reports Third Quarter and Nine Month 2023 Financial Results and Provides Business Update
BERKELEY HEIGHTS, N.J., Nov. 14, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention an...

CorMedix Inc. to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on November 14, 2023
BERKELEY HEIGHTS, N.J., Nov. 02, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention an...

CorMedix Inc. Announces Abstract Presentation at Upcoming IDWeek Conference
BERKELEY HEIGHTS, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention an...

CorMedix Inc. to Present at the Cantor Fitzgerald Global Healthcare Conference
BERKELEY HEIGHTS, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention a...

CorMedix Inc. Announces Publication of Phase 3 LOCK IT-100 Study Data in the Clinical Journal of The American Society of Nephrology
BERKELEY HEIGHTS, N.J., Sept. 08, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention a...

CorMedix Inc. to Present at the H.C. Wainwright Annual Global Investment Conference
BERKELEY HEIGHTS, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention a...

CorMedix Inc. Announces Issuance of U.S. Patent Covering Lead Product Defencath
BERKELEY HEIGHTS, N.J., Aug. 30, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention an...

CorMedix Inc. Reports Second Quarter and Six Month 2023 Financial Results and Provides Business Update
BERKELEY HEIGHTS, N.J., Aug. 08, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention an...

CorMedix Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Pre-Funded Warrants
BERKELEY HEIGHTS, N.J., June 28, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention an...

CorMedix Inc. Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
BERKELEY HEIGHTS, N.J., June 28, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention an...

CorMedix Inc. Announces FDA Acceptance of Resubmission of New Drug Application for DefenCath
BERKELEY HEIGHTS, N.J., June 21, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention an...

Cormedix Inc. Announces Strategic Initiative With Boston Medical Center to Reduce Health Disparities in Patients at Risk for Bloodstream Infections
BERKELEY HEIGHTS, N.J. , June 15, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention a...

Cormedix Inc. To Present At The Jefferies Healthcare Conference
BERKELEY HEIGHTS, N.J., May 30, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and...

CorMedix Inc. Announces Resubmission of New Drug Application for DefenCath
BERKELEY HEIGHTS, N.J., May 16, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and...

CorMedix Inc. To Report First Quarter 2023 Financial Results and Provide a Corporate Update on May 15, 2023
BERKELEY HEIGHTS, N.J., May 08, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and...

CorMedix Inc. to Participate in Two Upcoming Investor Conferences
BERKELEY HEIGHTS, N.J., May 03, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and...

CorMedix Inc. Announces Notice of Allowance for U.S. Patent Application Covering Lead Product DefenCath
BERKELEY HEIGHTS, N.J., May 01, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and...

Cormedix Inc. Announces Appointment of Robert A. Stewart to Its Board of Directors
BERKELEY HEIGHTS, N.J., April 17, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention a...

CorMedix Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Conference Call Scheduled for Today at 8:30 a.m. Eastern Time Conference Call Scheduled for Today at 8:30 a.m. Eastern Time

Cormedix Inc. to Report Fourth Quarter and Fiscal Year 2022 Financial Results and Provide a Corporate Update on March 30, 2023
BERKELEY HEIGHTS, N.J., March 21, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention a...

CorMedix Inc. Announces Regulatory and Manufacturing Updates
BERKELEY HEIGHTS, N.J., March 02, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention a...

CorMedix Inc. Announces Promotions in Commercial and Tech Ops
BERKELEY HEIGHTS, N.J., Jan. 17, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention an...